There is hardly any approved drug product for a cardiovascular ailment that utilizes nanotechnology. Although there are a few products in this category, they do not claim to be nano-therapeutics. An exhaustive evaluation of clinical trial databases indicates that in the near future, we may see some drug products in the market in this category. There are several similar investigational products by different groups across the globe. A comprehensive collection of published literature augurs the inclination of scientists in this field. The use of nanotechnology in cardiovascular is beneficial owing to Critical Quality Attributes that can be imparted based on the size, spatial arrangement of drug molecules, release profile, etc. In some cases, drug release characteristics have to be in sync with circadian rhythm, which can be easily obtained using this technology. The section of the book tries to highlight some of the aspects related to the exploration of nanotechnology in the case of cardiovascular treatment.